Written and medically reviewed by: Assoc. Prof. Cengiz Dibekoğlu, MD, General SurgeryLast updated:
Molecular Testing in Pancreatic Cancer
Germline genetic testing should be discussed for essentially every pancreatic cancer patient; tumor profiling helps in advanced disease.
Pancreatic adenocarcinoma care increasingly includes germline genetic testing for all patients — results can open platinum/PARP-related pathways and identify relatives who need screening. In advanced disease, somatic tumor profiling looks for uncommon but actionable alterations. CA 19-9 is a tumor marker, not a molecular panel, and does not replace genetic testing. Testing should answer a concrete treatment or hereditary question rather than create an unused report.
Educational schematic. Some structures may be simplified or emphasized for clarity; not an exact anatomical depiction.
© Cengiz Dibekoğlu — illustrative; not for unauthorized use
Figure summary
This educational figure shows: Pancreatic molecular testing.
Who may be a candidate?
- Patients with a new pancreatic cancer diagnosis
- People with advanced disease considering targeted options
- Families where hereditary risk counseling is needed
Possible advantages
- Supports informed consent with alternatives and recovery themes
- Highlights red flags that should trigger urgent contact
Limits & realistic expectations
- Cannot replace examination, imaging, or pathology
- Local protocols and tumor-board decisions may refine timing
- Outcomes vary with anatomy, stage, and comorbidity
Step-by-step overview
- 1
Confirm the diagnosis
Pathology and imaging establish pancreatic adenocarcinoma before panel selection.
- 2
Discuss germline testing
Discuss germline evaluation for most patients in current frameworks; arrange counseling and consent.
- 3
Stage-matched tumor profiling
In advanced disease, order somatic profiling that can change therapy.
- 4
Interpret with the board
Separate inherited findings from tumor-only changes before family cascade testing.
- 5
Act on results
Adjust systemic therapy and relative screening only when results are actionable.
Key points
- Key note inside
Somatic vs germline
Tumor-only findings are not automatically hereditary. Germline counseling uses separate consent and cascade-testing rules. Discuss timing, alternatives, and follow-up with your surgical team before you finalize a plan.
- Key note inside
Important
This page is for education. It is not medical advice and does not replace a visit with your physician.
Frequently asked questions
Should every pancreatic cancer patient discuss germline testing?
Guidelines increasingly support offering germline testing broadly because actionable findings are not limited to classic family histories.
Is CA 19-9 a molecular test?
No. It is a blood tumor marker and does not replace germline or somatic panels.
When is tumor (somatic) profiling most useful?
Mainly in advanced disease when results might open targeted options.
Will genetics delay needed surgery?
Urgent indicated operations proceed on clinical grounds; systemic choices may wait for results when safe.
More chapters in this hub
Molecular Testing Overview
Biomarkers answer specific treatment and hereditary questions
Molecular Testing in Colorectal Cancer
MMR/MSI, RAS/BRAF, and selected HER2/NTRK contexts
Molecular Testing in Gastric Cancer
HER2, PD-L1, CLDN18.2, and MSI/MMR timing
Molecular Testing in Breast Cancer
ER/PR/HER2 foundations and germline BRCA framework
Hereditary Cancers
Lynch, BRCA, FAP, CDH1, and genetic counseling in surgical patient language
Appointment / info
This page is for education. It is not medical advice and does not replace a visit with your physician.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.